SynthomerSYNT
SYNT logo
Fair Value
UK£1.28
Share price17 Aug
UK£0.9823.4% undervalued intrinsic discount
Loading
1Y49.85%
7D-1.01%

Future Earnings And Recovery Prospects Will Remain Under Pressure Amid Market Challenges

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
31 Mar 25
Updated
17 Aug 26
Views
306
Not Invested

Last Update 17 Aug 26

Fair value Decreased 13%

SYNT: Higher Profitability Assumptions And Execution On Plans Will Support Future Upside

Analysts have trimmed their fair value estimate for Synthomer from £1.47 to £1.28, even as recent price target increases on the stock point to updated views on revenue growth, profitability and future P/E assumptions.

Analyst Commentary

Recent research on Synthomer gives investors a mixed message. The stock has seen price targets set at 92 GBp and 100 GBp over the past several months, with ratings held at neutral levels. This suggests analysts are adjusting their models around valuation, execution risk and growth assumptions rather than making a clear call on upside or downside.

Bullish Takeaways

  • Bullish analysts have raised their price targets from 62 GBp to 92 GBp, then to 100 GBp, which signals more confidence in Synthomer's ability to support a higher equity value than previously modeled.
  • The move toward higher targets suggests upgraded views on revenue potential or profitability that can support the fair value range, even if those views are still framed within a Hold stance.
  • Retaining a Hold rating alongside higher targets can indicate that Synthomer's current share price is seen as closer to analysts' fair value estimates, which may reduce perceived valuation downside.
  • Incremental target moves also show that analysts are actively updating their Synthomer models, which gives investors more current reference points for comparing the stock to sector peers and broader indices.

Bearish Takeaways

  • Despite higher price targets, analysts have not shifted to a Buy recommendation, which flags ongoing caution around Synthomer's execution, earnings visibility or balance sheet risk.
  • The use of a Hold rating suggests analysts see limited near term valuation upside from current levels, given their current assumptions around growth and P/E.
  • Multiple target revisions over a short period can also signal uncertainty in forecasting Synthomer's earnings path, which may keep some investors on the sidelines.
  • The latest 100 GBp target, alongside a trimmed fair value estimate of £1.28, leaves a gap between different valuation views that investors may interpret as a sign of disagreement on Synthomer's long term earnings power.

What’s in the News for Synthomer

  • No recent Synthomer specific news stories are available from the primary news feed as of 14 August 2026.
  • No Synthomer coverage is available from periodicals in the secondary sources provided.
  • No key development items are listed for Synthomer in the data supplied.

Valuation Changes for Synthomer

  • Fair Value has moved from £1.47 to £1.28, which represents a reduction of around 13% in the updated model.
  • Discount Rate has edged up from 13.39% to 13.49%, a slight increase that generally implies a marginally higher required return in the valuation work.
  • Revenue Growth has been revised from 5.31% to 2.01%, which is a significant reduction in the forward growth assumption for Synthomer.
  • Net Profit Margin has shifted from 9.99% to 10.99%, a 1 percentage point increase that points to a higher expected level of profitability on each £ of revenue.
  • Future P/E has moved from 1.72x to 1.45x, indicating that the updated model applies a lower earnings multiple to Synthomer than before.
7 viewsusers have viewed this narrative update

Key Takeaways

  • Focus on specialty polymers, cost-reduction, and global diversification positions Synthomer to achieve better margins, stable earnings, and long-term growth in sustainable markets.
  • Expansion into eco-friendly products and high-growth regions leverages regulatory trends and urbanization, supporting multi-year revenue and margin improvement.
  • High leverage, slow market growth, overcapacity, shifting sustainability demands, and geopolitical risks constrain Synthomer's growth, margins, and ability to invest in innovation.

Catalysts

About Synthomer
    Manufactures and supplies specialised polymers and ingredients for coatings, construction, adhesives, and health and protection sectors.
What are the underlying business or industry changes driving this perspective?
  • The company's active pivot toward higher-value, specialty polymers-evidenced by the ongoing divestment of noncore, lower-margin businesses, portfolio simplification, and site rationalization-positions Synthomer to capitalize on long-term demand for sustainable and innovative chemicals. This shift is likely to enhance revenue quality, boost EBITDA margins, and support earnings growth by increasing pricing power and market relevance in growth segments.
  • Significant cost-reduction initiatives, alongside ongoing process automation and supply chain efficiencies, are generating higher operating leverage and margin improvement (e.g., a 110 bps gross margin gain YoY). As these cost programs deliver additional run-rate savings through 2026, Synthomer is set to unlock structural margin expansion and stronger free cash flow.
  • Emerging sustainability-related opportunities (such as ISCC+ certification, innovation in bio-based and biodegradable polymers, and marquee partnerships like Henkel) directly position Synthomer to benefit from regulatory and customer demand for low-emission, circular, and environmentally friendly products. This will drive new specialty product launches and open up higher-margin revenue streams.
  • Global trends toward urbanization, infrastructure investment, and healthcare spending (especially in Asia and emerging markets) are long-term tailwinds for demand in construction chemicals, adhesives, and medical/hygiene materials-core focus areas for Synthomer. This supports multi-year revenue growth potential as these markets recover and expand.
  • Geographical diversification and targeted capacity investments in the U.S. and Middle East, coupled with a more balanced sales mix, are reducing exposure to slower-growth European markets and volatile sectors, thereby improving earnings stability and providing a platform for medium-term top-line growth and improved net margins.
Synthomer Earnings and Revenue Growth

Synthomer Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

  • Analysts are assuming Synthomer's revenue will grow by 2.0% annually over the next 3 years.
  • Analysts are not forecasting that Synthomer will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Synthomer's profit margin will increase from -7.1% to the average GB Chemicals industry of 11.0% in 3 years.
  • If Synthomer's profit margin were to converge on the industry average, you could expect earnings to reach £210.0 million (and earnings per share of £1.28) by about August 2029, up from -£128.0 million today.
  • In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 1.5x on those 2029 earnings, up from -1.3x today. This future PE is lower than the current PE for the GB Chemicals industry at 19.6x.
  • Analysts expect the number of shares outstanding to remain consistent over the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 13.49%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?
  • Synthomer's high leverage and elevated net debt (with net debt to EBITDA at 4.8x and a suspended dividend until leverage falls below 3x) leave the company vulnerable to prolonged weak demand or cyclical downturns, constraining its ability to invest in growth and innovation, and putting pressure on earnings and cash flow.
  • The company's heavy exposure to Europe (nearly 50% of sales) in slow-growing, mature markets facing tightening environmental regulations could accelerate margin erosion and limit revenue growth, especially as the strategic shift toward the US and Asia is gradual and exposed to external risks.
  • Persistent industry overcapacity-especially in synthetic latex and emulsion polymers-combined with volatile or subdued end-market demand (notably in oil & gas, energy solutions, and nitrile for gloves), threatens sustained price competition and weaker revenues and profitability well beyond 2025.
  • Ongoing regulatory and consumer shifts toward sustainability and bio-based/biodegradable alternatives may erode Synthomer's traditional customer base in petrochemical-based products, requiring costly R&D and potentially compressing margins if Synthomer cannot quickly transition its portfolio.
  • The company remains exposed to volatile raw material costs, trade tariffs, and geopolitical supply chain risks, which could increase operating expenses, impact reliable product delivery, and compress net margins if such shocks persist or intensify.

Valuation

How have all the factors above been brought together to estimate a fair value?

  • The analysts have a consensus price target of £1.28 for Synthomer based on their expectations of its future earnings growth, profit margins and other risk factors.
  • However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of £2.0, and the most bearish reporting a price target of just £1.0.
  • In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be £1.9 billion, earnings will come to £210.0 million, and it would be trading on a PE ratio of 1.5x, assuming you use a discount rate of 13.5%.
  • Given the current share price of £0.99, the analyst price target of £1.28 is 22.7% higher.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Synthomer?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Comments

0 comments

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives

Fair Value vs Share Price

UK£1.28
vs UK£0.9823.4% undervalued intrinsic discount
PastFuture-127m2b2015201820212024202620272029Revenue UK£1.9bEarnings UK£210.0m
2%
Revenue growth
11%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Synthomer

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Undervalued with very low risk.

Market capUK£160.7m
PB0.2x
Estimated Growth1.8%
Dividend Yield0%
Full analysis

CEO & management

Michael Willome
CEO
3.7yrs
CEO Tenure

Manufactures and supplies specialised polymers and ingredients for coatings, construction, adhesives, and health and protection sectors.